Record Display for the EPA National Library Catalog

RECORD NUMBER: 121 OF 343

OLS Field Name OLS Field Data
Main Title Epidemiology in Risk Assessment for Regulatory Policy.
Author Whittemore, A. S. ;
CORP Author Stanford Univ., CA. Dept. of Family, Community and Preventive Medicine.;Health Effects Research Lab., Research Triangle Park, NC.
Publisher c1986
Year Published 1986
Report Number EPA-R-813495; EPA/600/J-86/531;
Stock Number PB90-233065
Additional Subjects Epidemiology ; Regulations ; Policies ; Graphs(Charts) ; Tables(Data) ; Bladder neoplasms ; Mortality ; Reprints ; Risk assessment ; Occupational exposure ; Toxic substances ; Environmental exposure pathways ; Lung neoplasms
Holdings
Library Call Number Additional Info Location Last
Modified
Checkout
Status
NTIS  PB90-233065 Most EPA libraries have a fiche copy filed under the call number shown. Check with individual libraries about paper copy. NTIS 08/27/1990
Collation 14p
Abstract
Epidemiology and risk assessment have several of the features needed to make the difficult decisions required in setting standards for levels of toxic agents in the workplace and environment. They differ in their aims, orientation, and time scale. While the distribution of disease provides the focus for epidemiologic research, concern for adverse effects of specific toxicants drives risk assessment. Most important, while epidemiology is a scientific field that draws upon medicine, demography, and statistics, risk assessment is a hybrid of science and policy that draws not only upon fields such as epidemiology, toxicology, chemistry and engineering, but also upon psychology, politics, economics, law and social justice. These inherent differences in emphasis, timing, and nature complicate the role played by epidemiology in risk assessment for regulatory policy. It will continue to play an essential part in regulatory decision-making. The role has placed epidemiologic findings and epidemiologists at the center of political controversies, with both positive and negative side effects of this new visibility. Ways to prevent the negative side effects and ways to increase the utility of epidemiologic data for regulatory risk assessment are explored. (Copyright (c) 1986 Pergamom Journals, Ltd.)